Clinical Trials
5
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
Phase 2
Withdrawn
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: PlaceboDrug: CHF 5074 1xDrug: CHF 5074 2x
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- CERESPIR
- Registration Number
- NCT01723670
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: CHF 5074 1xDrug: CHF 5074 2xDrug: PlaceboDrug: CHF 5074 3x
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- CERESPIR
- Target Recruit Count
- 96
- Registration Number
- NCT01303744
- Locations
- 🇺🇸
Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States
🇺🇸Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States
🇺🇸Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States
Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- CERESPIR
- Target Recruit Count
- 12
- Registration Number
- NCT01258452
- Locations
- 🇺🇸
Iberica Clinical Research Center, Eatontown, New Jersey, United States
Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: PlaceboDrug: CHF5074 1xDrug: CHF5074 2xDrug: CHF5074 3x
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- CERESPIR
- Target Recruit Count
- 48
- Registration Number
- NCT01203384
- Locations
- 🇺🇸
Iberica Clinical Research Center, Eatontown, New Jersey, United States
Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- CERESPIR
- Target Recruit Count
- 84
- Registration Number
- NCT00954252
- Locations
- 🇺🇸
Iberica Clinical Research Center, Eatontown, NJ 07724, New Jersey, United States
News
No news found